Imatron sells two more HeartScan centers
Less than a month after it agreed to sell its South San Francisco HeartScan center, Imatron has found a buyer for two of its remaining three facilities. The South San Francisco ultrafast CT developer signed an agreement March 22 with Newport Beach,
Less than a month after it agreed to sell its South San Francisco HeartScan center, Imatron has found a buyer for two of its remaining three facilities. The South San Francisco ultrafast CT developer signed an agreement March 22 with Newport Beach, CA-based firm Vital Imaging Companies for the sale of its Houston and Washington, DC, coronary artery disease risk-assessment centers. Imatron expects the sale to close by March 31.
Imatron sold the South San Francisco center Feb. 25 to Imaging Technology Group, also of South San Francisco, for $1.5 million in cash (SCAN 3/17/99). The sale represented a shift in Imatron's corporate strategy: Rather than trying to sell the HeartScan subsidiary whole, the company decided to sell each center individually.
Vital Imaging Companies includes Vital Imaging, a California firm that is not related to 3-D workstation developer Vital Images of Minneapolis. Vital Imaging intends to establish a network of facilities in major cities across the U.S., and plans to open a center this August in San Diego, according to Richard King, chairman and CEO. Vital Imaging would like to expand the scope of service at its centers to include full-body scans and open MRI, King said.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
